Expert opinion on the prescription practice of silodosin for treating benign prostatic hyperplasia patients in Indian clinical settings

Authors

  • Manjula S. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
  • Krishna Kumar M. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20240360

Keywords:

Benign prostatic hyperplasia, Silodosin, Dutasteride, Urinary tract infection, Mirabegron

Abstract

Background: The effectiveness and safety of silodosin compared to other drugs have been the subject of numerous studies to date, although the findings are debatable. So, this study aims to gather expert opinion on the prescription practice of silodosin for men with lower urinary tract symptoms leading to benign prostatic hyperplasia.

Methods: This cross-sectional, multiple-response questionnaire-based survey, included experts from various states across India with expertise in treating BPH. The study questionnaire, comprising 25 survey items on the management of BPH utilizing silodosin (8 mg) and other drug combinations to gather data via email or an online survey platform.

Results: Out of the 55 experts, 76% identified non-specific urinary tract infections as the most prevalent concomitant ailment in BPH patients. The majority of the experts (89.09%) recommended silodosin medication for these patients, and about 58% reported that patients might need to continue silodosin medication for three months. Another major benefit reported was its high selectivity for alpha 1A receptors (34.55%). However, 47% of experts reported retrograde ejaculation as a side effect, and 27% reported orthostatic hypotension. According to nearly 80% of responders, patients with BPH can use silodosin in combination with mirabegron (25/50 mg). A combination of silodosin and dutasteride was favoured by 67% of responders for BPH patients with acute urine retention.

Conclusions: The expert consensus has highlighted silodosin as an effective treatment option for LUTS in men with BPH in Indian settings. Silodosin and dutasteride combination were recommended by specialists for BPH patients with acute urine retention.

References

Roehrborn CG. Male Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH). Med Clin North Am. 2011;95(1):87-100.

Suresh K. Prostate health in India (BPH & Prostate Cancer). Arch Cancer Sci Ther. 2022;6(1):9-17.

Bhat SA, Rather SA, Islam N. An overview of benign prostatic hyperplasia and its appreciation in the Greco-Arab (Unani) system of medicine. Asian J Urol. 2022;9(2):109-18.

McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J Urol. 2011;185(5):1793-803.

Sausville J, Naslund M. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. Int J Clin Pract. 2010;64(13):1740-5.

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol. 2013;64(1):118-40.

MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int. 2004;94(9):1263-70.

Wilt T, MacDonald R, Rutks I, Cochrane Urology Group. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 1996;2010(1):2081.

Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). J Pharma Soc Japan. 2006;126:209-16.

Chapple CR, Montorsi F, Tammela TLJ, Wirth M, Koldewijn E, Fernández Fernández E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342-52.

Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies. J Urol. 2009;181(6):2634-40.

Kahkashan I, Chawdhary S, Tandon VR, Gupta R. To compare the efficacy and safety of silodosin and dutasteride combination with alfuzosin and dutasteride combination in patients of benign prostatic hyperplasia: a randomized, open label study. Int J Basic Clin Pharmacol. 2019;8(4):635-41.

Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial. Indian J Pharmacol. 2014;46(6):601.

Rossi M, Roumeguère T. Silodosin in the treatment of benign prostatic hyperplasia. DDDT. 2010;4:291-7.

Nabi N, Gupta S, Nabi NN, Gupta M, Banoo H, Nabi NG. A comparative study of silodosin and tamsulosin in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. JEMDS. 2016;5(77):5673-7.

Manohar CMS, Nagabhushana M, Karthikeyan VS, Sanjay RP, Kamath AJ, Keshavamurthy R. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH a double-blind randomized trial. Cent European J Urol. 2017;70(2):148-53.

Yokoyama T, Hara R, Fukumoto K, Fujii T, Jo Y, Miyaji Y, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol. 2011;18(3):225-30.

Chapple C, Castro-Diaz D, Chuang YC, Lee KS, Liao L, Liu SP, et al. Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study. Adv Ther. 2017;34(8):1953-65.

Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Use of an α1-Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy. J Urol. 1990;144(4):908-11.

Kawabe K, Yoshida M, Homma Y. Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98(5):1019-24.

Ding H, Du W, Hou ZZ, Wang HZ, Wang ZP. Silodosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Androl. 2013;15(1):121-8.

Yaraguppi AF, Jadav R. A comparative study of efficacy and safety of tamsulosin and silodosin in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. JEMDS. 2019;8(2):146-51.

Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016;48(2):134.

Yuan C, Jian Z, Ma Y, Wang M, Hu Q, Liu L. Systematic review and meta-analysis of efficacy and safety of silodosin in treatment of benign prostatic hyperplasia patients with lower urinary tract symptoms. Res J. 2020;10:1-15.

Downloads

Published

2024-02-22

Issue

Section

Original Research Articles